Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Its lead product candidates include Halneuron, which is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain; IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia; and IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was incorporated in 2012 and is headquartered in Alpharetta, Georgia.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
| ISIN Number | US92829J2033 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chairman and Chief Executive Officer |
| Dr. William L. Pridgen M.D. | Founder and Member of Scientific Advisory Board |
| Angela Walsh | Chief Financial Officer, Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 17, 2025 | SCHEDULE 13D/A | Filing |
| Mar 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 17, 2025 | SCHEDULE 13G | Filing |